SMMT on XNAS, Health Care, Summit Therapeutics Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 37% in a month and 40% in a year as the company lost $832.7M over 12 months.
BadFree cash flow negative $526.9M over the last 12 months
GoodInstitutional holders rose 24% to 294 in one quarter
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $208.4M.
31 Dec 2021RevenueNet incomeNet losstallest bar $565.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$208.4M
30 Jun 2026
–
-$215.7M
31 Mar 2026
–
-$189.4M
31 Dec 2025
–
-$219.2M
30 Sep 2025
–
-$231.8M
30 Jun 2025
–
-$565.7M
31 Mar 2025
–
-$62.9M
31 Dec 2024
$0
-$61.2M
30 Sep 2024
$0
-$56.3M
30 Jun 2024
–
-$60.4M
31 Mar 2024
–
-$43.5M
31 Dec 2023
$0
-$36.6M
30 Sep 2023
$0
-$21.3M
30 Jun 2023
$0
-$14.7M
31 Mar 2023
$0
-$542.4M
31 Dec 2022
–
-$19.2M
30 Sep 2022
$220K
-$21.4M
30 Jun 2022
$235K
-$16.8M
31 Mar 2022
$250K
-$21.4M
31 Dec 2021
$251K
-$27.1M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$832.7M
-$921.6M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.06
-$1.25
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-220%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$526.9M
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$629.8M
$238.6M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$629.8M (net cash)
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.71
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
14.1
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+24%
294 13F filers vs 238
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
17%
134.7M shares held by 13F filers (30 Sep 2026) of 799.8M outstanding (30 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
5.3%
42.3M shares sold short (30 Oct 2026) of 799.8M outstanding (30 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
9.4
42.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+3.3%
40.9M shares sold short in the report before, 42.3M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
49%
49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
83
83 articles in the last 7 days; its usual week has 8 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
10×
83 articles in the last 7 days; its usual week has 8.
Price $9.95 on 20 Nov 2026, -40% over 12 months (12-month range $9.95 to $26.38)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $102.2M in the last 12 months (the 12 months before: $22.5M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 8 published in the last 12 months, +167% on the 12 months before.Revenue per quarter. Revenue $0 in the latest quarter.Capital spending per quarter. Capital spending $396K in the latest quarter, +458% on a year earlier.Institutional holders (13F filers). 294 13F filers reported holding it in the latest 13F quarter, +30% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $251K, +36% on a year earlier; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $250K, +30% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $235K, +312% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $220K, -83% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $0; public on 21 Feb 2024
Quarter ended 30 Sep 2024: $0; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $0; public on 25 Feb 2025
Capital spending per quarter
Quarter ended 31 Dec 2021: $120K, +140% on a year earlier; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $361K, +826% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $293K, +94% on a year earlier; public on 12 Aug 2022
Quarter ended 31 Mar 2023: $53K, -85% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $20K, -93% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $53K; public on 8 Nov 2023
Quarter ended 31 Mar 2024: $4K, -92% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $63K, +215% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $58K, +9.4% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $14K; public on 25 Feb 2025
Quarter ended 31 Mar 2025: $422K, +10450% on a year earlier; public on 2 May 2025
Quarter ended 30 Sep 2025: $71K, +22% on a year earlier; public on 21 Oct 2025
Quarter ended 31 Dec 2025: $164K, +1071% on a year earlier; public on 24 Feb 2026
Quarter ended 31 Mar 2026: $245K, -42% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $909K; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $396K, +458% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 49; public on 14 Feb 2022
31 Mar 2022 report: 51; public on 16 May 2022
30 Jun 2022 report: 42; public on 15 Aug 2022
30 Sep 2022 report: 40; public on 14 Nov 2022
31 Dec 2022 report: 56; public on 14 Feb 2023
31 Mar 2023 report: 87; public on 15 May 2023
30 Jun 2023 report: 94; public on 14 Aug 2023
30 Sep 2023 report: 90; public on 14 Nov 2023
31 Dec 2023 report: 89; public on 14 Feb 2024
31 Mar 2024 report: 98; public on 15 May 2024
30 Jun 2024 report: 116; public on 14 Aug 2024
30 Sep 2024 report: 160; public on 14 Nov 2024
31 Dec 2024 report: 197; public on 14 Feb 2025
31 Mar 2025 report: 206; public on 15 May 2025
30 Jun 2025 report: 228; public on 14 Aug 2025
30 Sep 2025 report: 226; public on 14 Nov 2025
31 Dec 2025 report: 200; public on 17 Feb 2026
31 Mar 2026 report: 219; public on 15 May 2026
30 Jun 2026 report: 238; public on 14 Aug 2026
30 Sep 2026 report: 294; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $100.0M (12 Jun 2026), 28× its normal reading; higher than 93% of its own history.
Clustered insider buying: had 3 insiders buy $102.2M of its shares on the open market within 30 days (4 filings) Public on 13 Jun 2026.
H-1B/E-3 applications certified: H-1B/E-3 applications certified: 8 published in the last 12 months, +167% on the 12 months before.
Two or more unrelated kinds of records unusual within 30 days
9 Mar 2023confirmed
Confirmed across sources Insiders and Short interest and volume
Summit Therapeutics(SMMT): had 5.4M shares sold short in the 15 Feb 2023 report, 5.1× the same report last year, while it had 3 insiders buy $420.2M of its shares on the open market within 30 days (3 filings). Two unrelated kinds of activity within 28 days.
Short interest and volume: Short interest spike, became public on 10 Feb 2023
Short interest and volume: Short interest spike, became public on 28 Feb 2023
Insiders: Clustered insider buying, became public on 9 Mar 2023
Short interest and volume: Short interest spike, became public on 10 Mar 2023
The 15 Feb 2023 report against the 24 reports before it.
this reportearliernormal: 1.1MSee the evidence (4 changes)
Short interest and volume: Short interest spike became public on 10 Feb 2023
Summit Therapeutics had 4.3M shares sold short in the 31 Jan 2023 report, 6.1× the same report last year.
This period
4.3M (the 31 Jan 2023 report)
Normal report (median of 24 earlier)
968K
Typical spread (median absolute deviation)
329K
How far from its usual level
+6.8
Same report last year
706K
History used
1,859 days
the 31 Jan 2023 report24 earlier reportsnormal: 968K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Feb 2023
Summit Therapeutics had 5.4M shares sold short in the 15 Feb 2023 report, 5.1× the same report last year.
This period
5.4M (the 15 Feb 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
384K
How far from its usual level
+7.6
Same report last year
1.1M
History used
1,874 days
the 15 Feb 2023 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 10 Mar 2023
Summit Therapeutics had 6.0M shares sold short in the 28 Feb 2023 report, 5.0× the same report last year.
This period
6.0M (the 28 Feb 2023 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
577K
How far from its usual level
+5.7
Same report last year
1.2M
History used
1,887 days
the 28 Feb 2023 report24 earlier reportsnormal: 1.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
13 Jun 2026Insiders change
had 3 insiders buy $102.2M of its shares on the open market within 30 days (4 filings).
Who bought: Soni Manmeet Singh, Duggan Robert W, Zanganeh Mahkam.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 18.6M shares sold short in the 15 Jul 2024 report, 1.9× the same report last year.
Same report last year: 10.0M; its normal report is 11.1M.
See the evidence
This period
18.6M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
11.1M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+3.6
Same report last year
10.0M
History used
2,390 days
the 15 Jul 2024 report24 earlier reportsnormal: 11.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 20.3M shares sold short in the 28 Jun 2024 report, 2.0× the same report last year.
Same report last year: 10.2M; its normal report is 10.8M.
See the evidence
This period
20.3M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
10.8M
Typical spread (median absolute deviation)
930K
How far from its usual level
+6.9
Same report last year
10.2M
History used
2,373 days
the 28 Jun 2024 report24 earlier reportsnormal: 10.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 23.4M shares sold short in the 14 Jun 2024 report, 4.2× the same report last year.
Same report last year: 5.6M; its normal report is 10.8M.
See the evidence
This period
23.4M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
10.8M
Typical spread (median absolute deviation)
897K
How far from its usual level
+9.5
Same report last year
5.6M
History used
2,359 days
the 14 Jun 2024 report24 earlier reportsnormal: 10.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 21.3M shares sold short in the 31 May 2024 report, 4.6× the same report last year.
Same report last year: 4.6M; its normal report is 10.7M.
See the evidence
This period
21.3M (the 31 May 2024 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
897K
How far from its usual level
+7.9
Same report last year
4.6M
History used
2,345 days
the 31 May 2024 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 22.6M shares sold short in the 15 May 2024 report, 4.3× the same report last year.
Same report last year: 5.2M; its normal report is 10.6M.
See the evidence
This period
22.6M (the 15 May 2024 report)
Normal report (median of 24 earlier)
10.6M
Typical spread (median absolute deviation)
897K
How far from its usual level
+9.0
Same report last year
5.2M
History used
2,329 days
the 15 May 2024 report24 earlier reportsnormal: 10.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 23.4M shares sold short in the 30 Apr 2024 report, 4.6× the same report last year.
Same report last year: 5.1M; its normal report is 10.6M.
See the evidence
This period
23.4M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
10.6M
Typical spread (median absolute deviation)
897K
How far from its usual level
+9.7
Same report last year
5.1M
History used
2,314 days
the 30 Apr 2024 report24 earlier reportsnormal: 10.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 22.9M shares sold short in the 15 Apr 2024 report, 4.9× the same report last year.
Same report last year: 4.7M; its normal report is 10.4M.
See the evidence
This period
22.9M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
10.4M
Typical spread (median absolute deviation)
910K
How far from its usual level
+9.3
Same report last year
4.7M
History used
2,299 days
the 15 Apr 2024 report24 earlier reportsnormal: 10.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 21.8M shares sold short in the 28 Mar 2024 report, 5.5× the same report last year.
Same report last year: 3.9M; its normal report is 10.1M.
See the evidence
This period
21.8M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
692K
How far from its usual level
+11.4
Same report last year
3.9M
History used
2,281 days
the 28 Mar 2024 report24 earlier reportsnormal: 10.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 17.0M shares sold short in the 15 Mar 2024 report, 3.6× the same report last year.
Same report last year: 4.7M; its normal report is 10.0M.
See the evidence
This period
17.0M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
781K
How far from its usual level
+6.0
Same report last year
4.7M
History used
2,268 days
the 15 Mar 2024 report24 earlier reportsnormal: 10.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.0M shares sold short in the 29 Feb 2024 report, 2.6× the same report last year.
Same report last year: 6.0M; its normal report is 10.0M.
See the evidence
This period
16.0M (the 29 Feb 2024 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
805K
How far from its usual level
+5.0
Same report last year
6.0M
History used
2,253 days
the 29 Feb 2024 report24 earlier reportsnormal: 10.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.7M shares sold short in the 29 Sep 2023 report, 36× the same report last year.
Same report last year: 295K; its normal report is 4.9M.
See the evidence
This period
10.7M (the 29 Sep 2023 report)
Normal report (median of 24 earlier)
4.9M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+3.7
Same report last year
295K
History used
2,100 days
the 29 Sep 2023 report24 earlier reportsnormal: 4.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 33 13F filers open a new position in the quarter ended 31 Mar 2023, 5.5× the same quarter last year.
Same quarter last year: 6; its normal quarter is 8.5.
See the evidence
This period
33 (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
8.5
Typical spread (median absolute deviation)
4
How far from its usual level
+4.1
Same quarter last year
6
History used
2,922 days
the quarter ended 31 Mar 20238 earlier quartersnormal: 8.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Showing the newest 40 of 97 entries; narrow the window or the kind of data to see older ones.
Not listed: 142 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001599298
Ticker
SMMT
Domain
smmttx.com
Employer name
Summit Therapeutics, Inc. (1 unverified)
Hq location
FL|MIAMI|33131 (1 unverified)
Lobbying client
summit therapeutics
Name
Discuva Limited, Summit Corp plc, Summit International Holdings Limited (Cayman Islands), Summit (Oxford) Limited and 5 more
Uei
T3JZAH1DVLC9
DOL H-1B labor condition applications and PERM certifications90 data points19 Jun 2023 to 31 Aug 2026
Federal lobbying disclosures (LDA)2 records, 11 data points15 Apr 2020 to 30 Jun 2021
SEC Form 13F institutional holdings423 data points31 Mar 2015 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)171 records11 May 2016 to 18 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)406 data points31 Jan 2018 to 30 Oct 2026
SEC Form 4 insider transactions28 records, 56 data points10 Nov 2020 to 12 Jun 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4172 data points1 Aug 2018 to 20 Nov 2026